

---

## WilmerHale Reps Vtesse Inc. in Acquisition by Sucampo

APRIL 3, 2017

Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, and Vtesse Inc., a privately held rare disease company, announced that Sucampo has acquired Vtesse for upfront consideration of \$200 million. Sucampo funded the acquisition through the issuance of 2,782,678 shares of Sucampo Class A common stock and \$170 million of cash on hand; no external financing was utilized.

[Steven Singer](#) and [Gary Schall](#) led WilmerHale's representation of Vtesse in this transaction, with a team that included [Steven Barrett](#), [William Caporizzo](#), [Jeffrey Hermanson](#), [Scott Kilgore](#), [David Sluis](#), [Libby Ragan](#), [Ben Kelsey](#) and [Alan Wilson](#).

[View Vtesse's press release for details.](#)